BSD Medical Ships BSD-2000 Hyperthermia System to University of California San Francisco Medical Center

  BSD Medical Ships BSD-2000 Hyperthermia System to University of California
  San Francisco Medical Center

Business Wire

SALT LAKE CITY -- July 31, 2014

BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today
that the Company has shipped a BSD-2000 Hyperthermia System (BSD-2000) to the
prestigious University of California San Francisco Medical Center (UCSF
Medical Center). UCSF Medical Center is one of the nation's top 10 hospitals
and is recognized throughout the world for innovative patient care and
advanced technology (http://www.ucsfhealth.org/about/). UCSF Medical Center is
one of the premier providers of cancer care in the world. The UCSF Medical
Center Comprehensive Cancer Center received the prestigious designation of
"comprehensive" from the National Cancer Institute and ranks sixth nationwide
in National Cancer Institute research grants. UCSF Medical Center has 7,000
employees and numerous locations.

“We are excited to have the BSD-2000 placed in this prestigious cancer care
facility," stated Brian Ferrand, BSD's Vice President of Domestic Sales. UCSF
is one of the world's leading medical centers and has a long history of
providing innovative therapies, including hyperthermia. UCSF has previously
purchased a BSD-500 Hyperthermia System from BSD. We are pleased they have
decided to also offer the innovative capabilities of the BSD-2000 to their
patients."

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size, and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE marking approval is also recognized in many
countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
Tricia Ross, (310) 622-8226
tross@finprofiles.com
 
Press spacebar to pause and continue. Press esc to stop.